Indication
Evaluation of Pharmacokinetics of Sativex in the Absence and Presence of a Potent Inhibitor of CYP3A4
1 clinical trial
4 products
Product
Sativex and RifampicinClinical trial
A Phase I, Open-label, Randomised, Crossover Study in 3 Parallel Groups to Evaluate the Effect of Rifampicin, Ketoconazole, and Omeprazole on the Pharmacokinetics of Sativex in Healthy VolunteersStatus: Completed, Estimated PCD: 2008-03-01
Product
SativexProduct
Sativex and KetoconazoleProduct
Sativex + Omeprazole